Calculate optimal DAPT duration after coronary stenting based on bleeding vs. ischemic risk. DAPT score with stent type and OAC considerations.
The Dual Antiplatelet Therapy (DAPT) Duration Calculator helps determine the optimal duration of dual antiplatelet therapy after coronary stenting or acute coronary syndrome by balancing bleeding risk against ischemic risk. DAPT — typically aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) — is the cornerstone of post-PCI management, but the optimal duration remains one of the most debated topics in interventional cardiology.
Too short a course risks stent thrombosis and recurrent ischemic events, while excessively prolonged DAPT increases the risk of major bleeding. The DAPT Score, derived from the DAPT Study (12,866 patients), integrates multiple clinical factors to generate a composite risk score that predicts the net benefit of extended vs. shortened DAPT.
This calculator evaluates your clinical scenario including age, indication, stent type, comorbidities, and concomitant anticoagulation to provide a personalized DAPT duration recommendation. It also accounts for the increasingly common scenario of patients requiring oral anticoagulation (OAC) for atrial fibrillation, where triple therapy must be minimized to prevent life-threatening bleeding.
DAPT duration directly impacts two competing risks: stent thrombosis (potentially fatal) and major bleeding (potentially fatal). A personalized approach guided by the DAPT Score improves outcomes compared to a one-size-fits-all strategy. This calculator integrates AHA/ACC guidelines with the DAPT Score to provide actionable, evidence-based recommendations. Keep these notes focused on your operational context.
DAPT Score = Sum of weighted risk criteria: • Age ≥ 75: +1 point • Age 65–74: +0.5 points • Diabetes: +1 • Renal dysfunction (CrCl <60): +1 • Current smoking: +1 • Prior MI/ACS: +1 • Prior PCI/CABG: +1 • Heart failure (EF <30%): +1 • Paclitaxel-eluting stent: +1 • Small vessel (<3mm): +1 Higher score = higher bleeding risk → favor shorter DAPT
Result: DAPT Score: 2.5 — Recommended duration: 12 months
Age 68 (65–74 = 0.5 points), diabetes (1 point), prior MI (1 point) = 2.5 total points. This moderate bleeding risk balances against the ischemic benefit of extended DAPT in ACS. Standard 12-month DAPT is appropriate. No OAC simplifies management.
The landmark DAPT Study randomized 9,961 patients who had received coronary stents to either continued DAPT (30 months total) or aspirin alone after 12 months. Extended DAPT reduced stent thrombosis (0.4% vs 1.4%) and MI (2.1% vs 4.1%) but increased GUSTO moderate/severe bleeding (2.5% vs 1.6%) and all-cause mortality (2.0% vs 1.5%). The DAPT Score was developed to identify patients who benefit from extension vs. those at higher net risk.
Recent trials (STOPDAPT-2, TWILIGHT, TICO) have demonstrated that shorter DAPT (1–3 months) followed by P2Y12 monotherapy (dropping aspirin) may be equally effective with less bleeding in selected patients. This "de-escalation" strategy is particularly appealing for older patients and those with high bleeding risk.
Approximately 5–8% of PCI patients require concurrent oral anticoagulation for atrial fibrillation. The WOEST, PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials established that dual pathway therapy (OAC + single antiplatelet) is safer than triple therapy for most patients. Current guidelines recommend dropping aspirin after 1–4 weeks and continuing OAC + clopidogrel for 6–12 months.
Dual antiplatelet therapy combines aspirin (typically 81 mg) with a P2Y12 receptor inhibitor (clopidogrel 75 mg, ticagrelor 90 mg BID, or prasugrel 10 mg daily). This combination prevents platelet activation through two distinct pathways, dramatically reducing stent thrombosis and recurrent coronary events after PCI.
While DAPT reduces ischemic events, it increases bleeding risk — particularly gastrointestinal and intracranial hemorrhage. After 12 months, the incremental ischemic benefit decreases while bleeding risk accumulates linearly. The optimal strategy balances these competing risks based on individual patient factors.
Triple therapy is the combination of oral anticoagulation (OAC) + aspirin + P2Y12 inhibitor, used when a patient with atrial fibrillation (or another OAC indication) undergoes PCI. It dramatically increases bleeding risk (2–3× vs. DAPT alone) and should be minimized to the shortest possible duration, typically 1–4 weeks.
For ACS: ticagrelor or prasugrel are preferred over clopidogrel. Ticagrelor (PLATO) reduced cardiovascular death by 21%. Prasugrel (TRITON-TIMI 38) reduced stent thrombosis but increased bleeding. For stable angina/elective PCI: clopidogrel is standard. For patients on OAC: clopidogrel is preferred (lower bleeding risk in triple/dual pathway therapy).
DAPT interruption for non-cardiac surgery should be avoided within 30 days of BMS or 3–6 months of DES. If surgery is urgent, continue aspirin and stop P2Y12 inhibitor 5–7 days before (clopidogrel, ticagrelor) or 7 days before (prasugrel). Always consult the patient's cardiologist.
Premature DAPT discontinuation is the strongest predictor of stent thrombosis, which occurs acutely (clot formation within the stent) and is fatal in 20–40% of cases. The risk is highest in the first 30 days, but drug-eluting stents require longer DAPT because they delay endothelialization.